PMID: 3759565Aug 1, 1986Paper

Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma

International Journal of Radiation Oncology, Biology, Physics
D J GloverS E Vogl

Abstract

In animal models pre-treatment with misonidazole, a hypoxic cell radiosensitizer, enhances the antineoplastic effects of alkylating agent chemotherapy. Laboratory data suggest that hypoxic tumor cells may be more resistant to chemotherapy because of suboptimal drug delivery, reduced rates of cell division, or because hypoxia confers relative drug resistance. The therapeutic potential depends on the tumor type, doses of radiosensitizer and alkylating agent, the time interval between drug administration, and the ratio of sensitization of normal and malignant tissues. A Phase II trial of misonidazole and cyclophosphamide was initiated by the Eastern Cooperative Oncology Group to determine the response rate and toxicity in patients with metastatic renal cell cancer. Patients received 5 gm/m2 of misonidazole intravenously two hr before 1200 mg/m2 of cyclophosphamide every 3 wk. Patients with prior chemotherapy or radiotherapy received 1000 mg/m2 of cyclophosphamide. Misonidazole was discontinued after a total dose of 15 gm/m2. The median total misonidazole dose was 23.5 gm (range 4.5-34.5 gm). The median number of cyclophosphamide cycles was 2 (range 1-12). Of the 30 patients evaluable for response, only one patient had an objective...Continue Reading

References

Aug 1, 1975·Cancer·S K Carter, T H Wasserman
Jan 1, 1977·Journal of Surgical Oncology·W J Hrushesky, G P Murphy
Mar 1, 1982·International Journal of Radiation Oncology, Biology, Physics·T L PhillipsL W Brady
Mar 1, 1982·International Journal of Radiation Oncology, Biology, Physics·N J McNally
Mar 1, 1982·International Journal of Radiation Oncology, Biology, Physics·J J Clement, R K Johnson

❮ Previous
Next ❯

Citations

Jan 1, 1990·Urological Research·R Heicappell, R Ackermann
Apr 1, 1992·Investigational New Drugs·R S WitteD L Trump
Sep 30, 2006·Cancer Chemotherapy and Pharmacology·Monika K KrzyzanowskaGeorg A Bjarnason
Apr 16, 1998·International Journal of Urology : Official Journal of the Japanese Urological Association·J P van Brussel, G H Mickisch
Jan 1, 1992·International Journal of Radiation Oncology, Biology, Physics·C A WallenK T Wheeler
May 1, 1995·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·D J Chaplin
Mar 1, 1989·Cancer Treatment Reviews·D J Stewart, W K Evans

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

International Journal of Radiation Oncology, Biology, Physics
D W Siemann
International Journal of Radiation Oncology, Biology, Physics
J T Roberts, N M Bleehen
International Journal of Radiation Oncology, Biology, Physics
J T RobertsM I Walton
International Journal of Radiation Oncology, Biology, Physics
M Hinchliffe, N J McNally
International Journal of Radiation Oncology, Biology, Physics
C Zachariae, J Overgaard
© 2021 Meta ULC. All rights reserved